Gene editing is a new and accurate genetic engineering technology that can modify specific target genes in the genome of an organism.
Gene editing technology refers to the ability for humans to "edit" targeted genes to achieve modifications to specific DNA fragments.
Gene editing relies on genetically engineered nucleases, also known as "molecular scissors," to produce site-specific double-strand breaks (DSBs) at specific locations in the genome, inducing organisms to connect via non-homologous end junctions (NHEJ) or homologous Source Recombination (HR) to repair DSB because this repair process is error-prone, resulting in targeted mutations

In 2021, the global Gene Editing Technology market size will be US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027.
This report focuses on the global Gene Editing Technology status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Gene Editing Technology development in North America, Europe, Japan, China, Southeast Asia, India, etc.

Global Gene Editing Technology Scope and Market Size
Gene Editing Technology market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gene Editing Technology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Homologous Recombination
Meganuclease

Segment by Application
Agriculture
Medical
Other

By Region
North America
Europe
Japan
China
Southeast Asia
India

By Company
Thermo Fisher Scientific
SIGMA ALDRICH
Dharmacon
Cellectics
CRISPR Therapeutics
AstraZeneca
Bio Rad
Allele Biotech
Recombinetics
Lonza
GE Healthcare
Editas Medicine
Agilent Technologies
QIAGEN NV